Addition of daratumumab to multiple myeloma backbone regimens significantly improves clinical outcomes: a systematic review and meta-analysis of randomised controlled trials

Daratumumab has shown clinical benefit in multiple myeloma. We aimed to evaluate the safety and efficacy of adding daratumumab to backbone anti-myeloma treatments. Systematic search was performed up to August 2021 to identify randomised controlled trials comparing the outcomes of backbone therapy wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiss, Szabolcs, Gede, Noémi, Hegyi, Péter, Nagy, Bettina, Deák, Rita, Dembrovszky, Fanni, Bunduc, Stefania, Erőss, Bálint, Leiner, Tamás, Szakács, Zsolt, Alizadeh, Hussain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8578422/
https://www.ncbi.nlm.nih.gov/pubmed/34754015
http://dx.doi.org/10.1038/s41598-021-01440-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8578422/
https://www.ncbi.nlm.nih.gov/pubmed/34754015
http://dx.doi.org/10.1038/s41598-021-01440-x

Ejemplares similares